Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. have entered into a strategic alliance to research and develop applications for a patent covering water-soluble cannabinoids. The collaboration centers on AXIM's U.S. Patent No. 11,542,226 B2, which addresses a fundamental limitation of traditional cannabinoids: their inability to dissolve in water, significantly impairing absorption by the body.
Under the agreement, AXIM assigned Medical Marijuana, Inc. a fifty percent right, title, and economic interest in the patent and all associated intellectual property. This includes rights to existing and future U.S. and foreign patents, licensing, enforcement, and monetization proceeds, and claims for past infringement. Medical Marijuana, Inc. paid $600,000 for this assignment through a secured promissory note. Concurrently, the companies entered a Consulting Agreement where AXIM will provide research and development services focused on developing applications for the patent technology. The consulting agreement has an initial term of one year expiring in January 2027, with Medical Marijuana, Inc. paying AXIM $62,500 per month for services.
The technological advancement represented by this patent has significant implications for medical treatment. The patented molecular engineering creates novel molecules that link cannabinoids to complementary compounds, improving delivery mechanisms and therapeutic effectiveness. These engineered polyfunctional cannabinoids are more than 300 times more water-soluble than natural cannabinoids, enabling significantly improved absorption and therapeutic delivery. This enhanced solubility could lead to more potent responses with potentially lower therapeutic doses, avoiding toxic side effects associated with higher concentrations.
Dr. Timothy R. Scott, who returned as president of Medical Marijuana, Inc. in conjunction with this alliance, stated the company has "tremendous confidence in the AXIM team's ability to provide R&D support for the development of commercialized uses of the Patent technology." He emphasized that "the potential for developing enhanced administration of water soluble CBD and other cannabinoids for certain ailments and conditions is a major development" for the company.
AXIM President Catalina Valencia noted that "the water solubility of CBD and other cannabinoids is a significant development for the improved administration and increased potency of cannabinoids." She explained that "the Patent could result in the development of a drug or treatment, most likely in the form of sublingual administration, able to treat a variety of conditions including anxiety or seizures." The technology offers treatment potential for conditions where traditional lipophilic cannabinoids have demonstrated limited bioavailability.
This alliance represents a strategic move in the cannabinoid industry, combining Medical Marijuana, Inc.'s market knowledge and distribution channels with AXIM's patented technology. The companies believe the partnership presents opportunities to accelerate uses of the patent technology and unlock potential for both organizations. The development of water-soluble cannabinoids could expand treatment applications and improve therapeutic outcomes for patients using cannabinoid-based therapies.
